Meta-analysis: Interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

Journal of Viral Hepatitis

Volumn 17, Issue 4, 2010, Pages 287-292

  Miyake, Y ^a   Takaki, A ^a   Iwasaki, Y ^a   Yamamoto, K ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Hepatitis C; Hepatocellular carcinoma; Interferon; Milan criteria; Prevention; Recurrence

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A;

ADJUVANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 77950220516     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01181.x     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 : 74 108.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 : 2557 2576.
3. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005 19 : 3 23.
4. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995 346 : 1051 1055.
5. International Interferon-α Hepatocellular Carcinoma Study Group. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998 351 : 1535 1539.
6. Imai Y, Kawata S, Tamura S et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998 129 : 94 99.
7. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999 131 : 174 181.
8. Takenaka K, Yamamoto K, Taketomi A et al. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology 1995 22 : 20 24.
9. Sasaki Y, Yamada T, Tanaka H et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 2006 244 : 771 780.
10. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996 334 : 693 699.
11. Kamiyama T, Nakanishi K, Yokoo H et al. Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol 2009 16 : 1560 1571.
12. Tanaka H, Shiota G, Kawasaki H. Changes in glucose tolerance after interferon-alpha therapy in patients with chronic hepatitis C. J Med 1997 28 : 335 346.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 7 : 177 188.
14. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994 50 : 1088 1101.
15. Suou T, Mitsuda A, Koda M et al. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001 20 : 301 311.
16. Shiratori Y, Shiina S, Teratani T et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003 138 : 299 306.
17. Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005 48 : 71 75.
18. Kudo M, Sakaguchi Y, Chung H et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 2007 72 (Suppl. 1 132 138.
19. Jeong SC, Aikata H, Katamura Y et al. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007 13 : 5343 5350.
20. Kubo S, Nishiguchi S, Hirohashi K et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001 134 : 963 967.
21. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002 89 : 418 422.
22. Uenishi T, Nishiguchi S, Tanaka S, Yamamoto T, Takemura S, Kubo S. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2008 98 : 358 362.
23. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005 48 : 64 70.
24. Jeong S, Aikata H, Katamura Y et al. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007 13 : 5188 5195.
25. Shiratori Y, Shiina S, Imamura M et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995 22 : 1027 1033.
26. Mazzaferro V, Romito R, Schiavo M et al. HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006 44 : 1543 1554.
27. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000 132 : 517 524.
28. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998 352 : 1426 1432.
29. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1485 1492.
30. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
31. Yano H, Iemura A, Haramaki M et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999 29 : 1708 1717.
32. Llovet JM, Sala M, Castells L et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000 31 : 54 58.
33. Shiratori Y, Nakata R, Shimizu N et al. IFN-beta Research Group. High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group. Dig Dis Sci 2000 45 : 2414 2421.
34. Han Q, Liu Z, Kang W, Li H, Zhang L, Zhang N. Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial. Dig Dis Sci 2008 53 : 2238 2245.
35. Ikeda K, Arase Y, Saitoh S et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000 32 : 228 232.